Hemab Therapeutics Hldgs Analyst Price Targets

Wall Street analyst price targets and consensus rating for Hemab Therapeutics Hldgs (COAG).

Price Target Range — 3 Quarters

Analyst Consensus — 7 Analysts

7Buy

Consensus RatingBuy# Analysts7Avg. Consensus PT$55Upside to Avg. PT+82.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 15, 2026	JP Morgan	Joyce Zhou	Initiate	Overweight	$70
Oct 12, 2026	Rodman & Renshaw	Michael G. King Jr.	Initiate	Buy	$56
Aug 12, 2026	Wedbush	David Nierengarten	PT Raise	Outperform	$55→$64
Aug 11, 2026	HC Wainwright & Co.	Emily Bodnar	PT Raise	Buy	$52→$60
Jul 13, 2026	Jefferies	Maury Raycroft	PT Raise	Buy	$39→$47
Jul 13, 2026	Wedbush	David Nierengarten	PT Raise	Outperform	$42→$55
Jul 13, 2026	HC Wainwright & Co.	Emily Bodnar	PT Raise	Buy	$40→$52
Jun 26, 2026	HC Wainwright & Co.	Emily Bodnar	Maintained	Buy	$40
Jun 17, 2026	HC Wainwright & Co.	Emily Bodnar	Initiate	Buy	$40
May 26, 2026	Wedbush	David Nierengarten	Initiate	Outperform	$42
May 26, 2026	Jefferies	Maury Raycroft	Initiate	Buy	$39
May 26, 2026	Evercore ISI Group	Cory Kasimov	Initiate	Outperform	$50
May 26, 2026	Goldman Sachs	Richard Law	Initiate	Buy	$36

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
JP Morgan Initiates Coverage On Hemab Therapeutics Hldgs with Overweight Rating, Announces Price Target of $70

JP Morgan analyst Joyce Zhou initiates coverage on Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Overweight rating and announces Price Target of $70.

Benzinga Newsdesk

PRO
Rodman & Renshaw Initiates Coverage On Hemab Therapeutics Hldgs with Buy Rating, Announces Price Target of $56

Rodman & Renshaw analyst Michael G. King Jr. initiates coverage on Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Buy rating and announces Price Target of $56.

Benzinga Newsdesk

PRO
Wedbush Maintains Outperform on Hemab Therapeutics Hldgs, Raises Price Target to $64

Wedbush analyst David Nierengarten maintains Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Outperform and raises the price target from $55 to $64.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Hemab Therapeutics Hldgs, Raises Price Target to $60

HC Wainwright & Co. analyst Emily Bodnar maintains Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Buy and raises the price target from $52 to $60.

Benzinga Newsdesk

PRO
Jefferies Maintains Buy on Hemab Therapeutics Hldgs, Raises Price Target to $47

Jefferies analyst Maury Raycroft maintains Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Buy and raises the price target from $39 to $47.

Benzinga Newsdesk

PRO
CORRECTION: Wedbush Maintains Outperform on Hemab Therapeutics Hldgs, Raises Price Target To $55

Wedbush analyst David Nierengarten maintains Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Outperform and raises the price target from $42 to $55.

Benzinga Newsdesk

Hemab Therapeutics Holdings Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Hemab Therapeutics Hldgs Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
JP Morgan Initiates Coverage On Hemab Therapeutics Hldgs with Overweight Rating, Announces Price Target of $70

PRO
Rodman & Renshaw Initiates Coverage On Hemab Therapeutics Hldgs with Buy Rating, Announces Price Target of $56

PRO
Wedbush Maintains Outperform on Hemab Therapeutics Hldgs, Raises Price Target to $64

PRO
HC Wainwright & Co. Maintains Buy on Hemab Therapeutics Hldgs, Raises Price Target to $60

PRO
Jefferies Maintains Buy on Hemab Therapeutics Hldgs, Raises Price Target to $47

PRO
CORRECTION: Wedbush Maintains Outperform on Hemab Therapeutics Hldgs, Raises Price Target To $55

People Also Watch

People Also Watch

Hemab Therapeutics Holdings Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Hemab Therapeutics Hldgs Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROJP Morgan Initiates Coverage On Hemab Therapeutics Hldgs with Overweight Rating, Announces Price Target of $70

PRORodman & Renshaw Initiates Coverage On Hemab Therapeutics Hldgs with Buy Rating, Announces Price Target of $56

PROWedbush Maintains Outperform on Hemab Therapeutics Hldgs, Raises Price Target to $64

PROHC Wainwright & Co. Maintains Buy on Hemab Therapeutics Hldgs, Raises Price Target to $60

PROJefferies Maintains Buy on Hemab Therapeutics Hldgs, Raises Price Target to $47

PROCORRECTION: Wedbush Maintains Outperform on Hemab Therapeutics Hldgs, Raises Price Target To $55

People Also Watch

People Also Watch

PRO
JP Morgan Initiates Coverage On Hemab Therapeutics Hldgs with Overweight Rating, Announces Price Target of $70

PRO
Rodman & Renshaw Initiates Coverage On Hemab Therapeutics Hldgs with Buy Rating, Announces Price Target of $56

PRO
Wedbush Maintains Outperform on Hemab Therapeutics Hldgs, Raises Price Target to $64

PRO
HC Wainwright & Co. Maintains Buy on Hemab Therapeutics Hldgs, Raises Price Target to $60

PRO
Jefferies Maintains Buy on Hemab Therapeutics Hldgs, Raises Price Target to $47

PRO
CORRECTION: Wedbush Maintains Outperform on Hemab Therapeutics Hldgs, Raises Price Target To $55